Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
Biomea Fusion (Nasdaq: BMEA) has announced a conference call and webcast scheduled for Wednesday, October 30th at 4:30 pm ET. The event will focus on two key announcements:
1. Introduction of BMF-650, their lead clinical candidate, described as a next-generation, potent, selective, oral small-molecule GLP-1 receptor agonist (GLP-1 RA).
2. Presentation of preclinical study results examining the synergistic benefits of combining BMF-219 with a GLP-1 RA-based therapy.
The webcast will be accessible to registered attendees through Biomea's investor website. A replay will be available after the event.
Biomea Fusion (Nasdaq: BMEA) ha annunciato una call di conferenza e una webcast programmata per mercoledì 30 ottobre alle 16:30 ET. L'evento si concentrerà su due annunci chiave:
1. Introduzione di BMF-650, il loro principale candidato clinico, descritto come un agonista del recettore GLP-1 (GLP-1 RA) orale, selettivo e potente di nuova generazione.
2. Presentazione dei risultati di uno studio preclinico che esamina i benefici sinergici della combinazione di BMF-219 con una terapia basata su GLP-1 RA.
La webcast sarà accessibile agli iscritti tramite il sito web degli investitori di Biomea. Una registrazione sarà disponibile dopo l'evento.
Biomea Fusion (Nasdaq: BMEA) ha anunciado una llamada de conferencia y una transmisión web programada para el miércoles 30 de octubre a las 4:30 p.m. ET. El evento se centrará en dos anuncios clave:
1. Introducción de BMF-650, su principal candidato clínico, descrito como un potente y selectivo agonista del receptor GLP-1 (GLP-1 RA) de nueva generación, oral.
2. Presentación de los resultados de un estudio preclínico que examina los beneficios sinérgicos de combinar BMF-219 con una terapia basada en GLP-1 RA.
La transmisión estará disponible para los asistentes registrados a través del sitio web para inversores de Biomea. Una repetición estará disponible después del evento.
Biomea Fusion (Nasdaq: BMEA)는 10월 30일 수요일 오후 4시 30분 ET에 예정된 컨퍼런스 콜 및 웹캐스트를 발표했습니다. 이 이벤트는 두 가지 주요 발표에 초점을 맞출 것입니다:
1. 차세대의 강력하고 선택적인 경구용 소분자 GLP-1 수용체 작용제(GLP-1 RA)인 주요 임상 후보 BMF-650의 소개.
2. BMF-219와 GLP-1 RA 기반 치료의 병합의 시너지 효과를 검사하는 전임상 연구 결과 발표.
웹캐스트는 Biomea의 투자자 웹사이트를 통해 등록된 참석자들이 접근할 수 있습니다. 이벤트 후에는 재생할 수 있는 녹화가 제공됩니다.
Biomea Fusion (Nasdaq: BMEA) a annoncé une conférence téléphonique et un webcast prévus pour mercredi 30 octobre à 16h30 ET. L'événement se concentrera sur deux annonces clés :
1. Introduction de BMF-650, leur principal candidat clinique, décrit comme un agoniste du récepteur GLP-1 (GLP-1 RA) de nouvelle génération, puissant et sélectif, à administration orale.
2. Présentation des résultats d'une étude préclinique examinant les bénéfices synergiques de la combinaison de BMF-219 avec une thérapie basée sur le GLP-1 RA.
Le webcast sera accessible aux participants enregistrés via le site web des investisseurs de Biomea. Un replay sera disponible après l'événement.
Biomea Fusion (Nasdaq: BMEA) hat einen Konferenzanruf und ein Webcast für Mittwoch, den 30. Oktober um 16:30 Uhr ET angekündigt. Die Veranstaltung wird sich auf zwei wichtige Ankündigungen konzentrieren:
1. Einführung von BMF-650, ihrem führenden klinischen Kandidaten, der als ein leistungsstarker, selektiver, oraler Kleinstmolekül- GLP-1-Rezeptor-Agonist (GLP-1 RA) der nächsten Generation beschrieben wird.
2. Präsentation von Ergebnissen einer präklinischen Studie, die die synergistischen Vorteile der Kombination von BMF-219 mit einer auf GLP-1 RA basierenden Therapie untersucht.
Das Webcast ist für registrierte Teilnehmer über die Investorenseite von Biomea zugänglich. Nach der Veranstaltung wird eine Wiederholung verfügbar sein.
- Introduction of BMF-650, a new oral GLP-1 receptor agonist, potentially expanding Biomea's product pipeline
- Preclinical data on combining BMF-219 with GLP-1 RA therapy, suggesting potential synergistic benefits
- None.
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Wednesday, October 30th at 4:30 pm ET to announce our lead clinical candidate, BMF-650 – a next-generation, potent, selective, oral small-molecule GLP-1 receptor agonist (GLP-1 RA) and to share results of preclinical studies investigating the synergistic benefits of combining BMF-219 with a GLP-1 RA-based therapy.
Conference Call and Webcast Details
Webcast of Biomea’s investor update on Wednesday, October 30th at 4 pm ET will be available to registered attendees under the Investors and Media section of the company’s website at https://investors.biomeafusion.com/news-events/events.
A replay of the presentation will be archived on Biomea’s site following the event.
About Obesity
Obesity is a chronic disease necessitating long-term management, associated with diminished life expectancy and a spectrum of severe health complications. These include metabolic disorders such as type 2 diabetes and non-alcoholic fatty liver disease; cardiovascular diseases like heart attack, stroke, and hypertension; and increased risks of chronic kidney disease, certain cancers, and chronic inflammation. The CDC estimates that over
About GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone that plays a vital role in glucose homeostasis and appetite regulation. GLP-1 receptor agonists are a class of medications that bind to and activate GLP-1 receptors, mimicking the effects of native GLP-1. These agents have demonstrated robust clinical efficacy in improving glycemic control, promoting weight loss, and enhancing insulin sensitivity in individuals with type 2 diabetes and obesity.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design, and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X, and Facebook.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.
Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea Fusion’s business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
FAQ
What is Biomea Fusion (BMEA) announcing on October 30th, 2024?
What is BMF-650, the new drug candidate from Biomea Fusion (BMEA)?
When and where can investors access Biomea Fusion's (BMEA) October 30th, 2024 webcast?